150 related articles for article (PubMed ID: 37732127)
1. Development and validation of a non-invasive model for predicting significant fibrosis based on patients with nonalcoholic fatty liver disease in the United States.
Guo Y; Shen B; Xue Y; Li Y
Front Endocrinol (Lausanne); 2023; 14():1207365. PubMed ID: 37732127
[TBL] [Abstract][Full Text] [Related]
2. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
3. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a non-invasive model for diagnosing HBV-related liver cirrhosis.
Zhang X; Huang P; Wang X; Zhou K; Chen F; Zhou C; Yu L; Lu Q; Zhou J; Hu J; Wang Z
Clin Chim Acta; 2021 Dec; 523():525-531. PubMed ID: 34748781
[TBL] [Abstract][Full Text] [Related]
5. A Prediction Model Based on Noninvasive Indicators to Predict the 8-Year Incidence of Type 2 Diabetes in Patients with Nonalcoholic Fatty Liver Disease: A Population-Based Retrospective Cohort Study.
Cai X; Zhu Q; Cao Y; Liu S; Wang M; Wu T; Hong J; Ahmat A; Aierken X; Li N
Biomed Res Int; 2021; 2021():5527460. PubMed ID: 34095297
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive prediction nomogram for predicting significant fibrosis in patients with metabolic-associated fatty liver disease: a cross-sectional study.
Zhang F; Han Y; Mao Y; Zheng G; Liu L; Li W
Ann Med; 2024 Dec; 56(1):2337739. PubMed ID: 38574396
[TBL] [Abstract][Full Text] [Related]
7. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.
Harrison SA; Ratziu V; Boursier J; Francque S; Bedossa P; Majd Z; Cordonnier G; Sudrik FB; Darteil R; Liebe R; Magnanensi J; Hajji Y; Brozek J; Roudot A; Staels B; Hum DW; Megnien SJ; Hosmane S; Dam N; Chaumat P; Hanf R; Anstee QM; Sanyal AJ
Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):970-985. PubMed ID: 32763196
[TBL] [Abstract][Full Text] [Related]
8. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
9. Association of weight-adjusted-waist index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study based on NHANES.
Hu Q; Han K; Shen J; Sun W; Gao L; Gao Y
Eur J Med Res; 2023 Aug; 28(1):263. PubMed ID: 37537679
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a noninvasive clinical scoring system to predict significant fibrosis in patients with nonalcoholic fatty liver disease.
Jin W; Xu Y; Zhu W; Xia Z; Wu J
Clin Chim Acta; 2021 Mar; 514():48-53. PubMed ID: 33333040
[TBL] [Abstract][Full Text] [Related]
11. Comments on validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
Hong JG; Yan LJ; Li X; Yao SY; Su P; Li HC; Ding ZN; Wang DX; Dong ZR; Li T
World J Gastroenterol; 2022 Feb; 28(6):689-692. PubMed ID: 35317426
[TBL] [Abstract][Full Text] [Related]
12. Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease.
Siddiqui MS; Patidar KR; Boyett S; Luketic VA; Puri P; Sanyal AJ
Liver Int; 2016 Apr; 36(4):572-9. PubMed ID: 26713759
[TBL] [Abstract][Full Text] [Related]
13. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
Sanyal AJ; Foucquier J; Younossi ZM; Harrison SA; Newsome PN; Chan WK; Yilmaz Y; De Ledinghen V; Costentin C; Zheng MH; Wai-Sun Wong V; Elkhashab M; Huss RS; Myers RP; Roux M; Labourdette A; Destro M; Fournier-Poizat C; Miette V; Sandrin L; Boursier J
J Hepatol; 2023 Feb; 78(2):247-259. PubMed ID: 36375686
[TBL] [Abstract][Full Text] [Related]
14. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictive score for detecting nonalcoholic fatty liver disease with significant fibrosis in patients with metabolic syndrome.
Kositamongkol C; Charernboon T; Chaisathaphol T; Washirasaksiri C; Auesomwang C; Sitasuwan T; Charatcharoenwitthaya P; Phisalprapa P
Medicine (Baltimore); 2021 Nov; 100(44):e27640. PubMed ID: 34871234
[TBL] [Abstract][Full Text] [Related]
16. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese.
Ooi GJ; Burton PR; Doyle L; Wentworth JM; Bhathal PS; Sikaris K; Cowley MA; Roberts SK; Kemp W; O'Brien PE; Brown WA
Obes Surg; 2017 Jan; 27(1):115-125. PubMed ID: 27220852
[TBL] [Abstract][Full Text] [Related]
17. A Nomogram Model Based on Noninvasive Bioindicators to Predict 3-Year Risk of Nonalcoholic Fatty Liver in Nonobese Mainland Chinese: A Prospective Cohort Study.
Cai X; Aierken X; Ahmat A; Cao Y; Zhu Q; Wu T; Li N
Biomed Res Int; 2020; 2020():8852198. PubMed ID: 33204721
[TBL] [Abstract][Full Text] [Related]
18. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
[TBL] [Abstract][Full Text] [Related]
19. The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999-2004.
Li L; Huang Q; Yang L; Zhang R; Gao L; Han X; Ji L; Zou X
Nutrients; 2022 Mar; 14(6):. PubMed ID: 35334881
[TBL] [Abstract][Full Text] [Related]
20. Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD.
Feng G; Zheng KI; Li YY; Rios RS; Zhu PW; Pan XY; Li G; Ma HL; Tang LJ; Byrne CD; Targher G; He N; Mi M; Chen YP; Zheng MH
J Hepatobiliary Pancreat Sci; 2021 Jul; 28(7):593-603. PubMed ID: 33908180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
